Literature DB >> 1694672

Degradation of airway neuropeptides by human lung tryptase.

E K Tam1, G H Caughey.   

Abstract

Several lines of evidence suggest a possible role for mast cell proteases in modulating the biologic effects of neuropeptides. To explore the potential of such interactions in human airway, we examined the activity of human tryptase, the major secretory protease of human lung mast cells, against several neuropeptides with proposed regulatory functions in human airway. Using highly purified tryptase obtained from extracts of human lung, we determined the sites and rats of hydrolysis of vasoactive intestinal peptide (VIP), peptide histidine-methionine (PHM), calcitonin gene-related peptide (CGRP), and the tachykinins substance P (SP), neurokinin A (NKA), and neurokinin B (NKB). Tryptase hydrolyzes VIP rapidly at several sites (Arg12, Arg14, Lys20, and Lys21) with an overall kcat/Km of 1.5 x 10(5) M-1 s-1 and hydrolyzes PHM primarily at a single site (Lys20) with a kcat/Km of 1.9 x 10(4) M-1 s-1. Tryptase also rapidly hydrolyzes CGRP at two sites (Arg18 and Lys24) with a kcat/Km of 2.7 x 10(5) M-1 s-1. The tachykinins are not hydrolyzed by tryptase. These observations raise the possibility that tryptase-mediated degradation of the bronchodilators VIP and PHM combined with exaggerated mast cell release of tryptase may contribute to the increase in bronchial responsiveness and the decrease in immunoreactive VIP in airway nerves associated with asthma. The favorable rates of hydrolysis of CGRP suggest that tryptase may also terminate the effects of CGRP on bronchial and vascular smooth muscle tone and permeability.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694672     DOI: 10.1165/ajrcmb/3.1.27

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  37 in total

1.  The structure of the human betaII-tryptase tetramer: fo(u)r better or worse.

Authors:  C P Sommerhoff; W Bode; P J Pereira; M T Stubbs; J Stürzebecher; G P Piechottka; G Matschiner; A Bergner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

Review 2.  Importance of mast cells in the pathophysiology of asthma.

Authors:  Seong H Cho; Andrea J Anderson; Chad K Oh
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

Review 3.  The diverse effects of mast cell mediators.

Authors:  Colleen Hines
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

Review 4.  Potential targets for intervention in radiation-induced heart disease.

Authors:  M Boerma; M Hauer-Jensen
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

Review 5.  Mast cell tryptases and chymases in inflammation and host defense.

Authors:  George H Caughey
Journal:  Immunol Rev       Date:  2007-06       Impact factor: 12.988

6.  Inhibition of calcium-independent phospholipase A2 prevents inflammatory mediator production in pulmonary microvascular endothelium.

Authors:  Prerna Rastogi; Jane McHowat
Journal:  Respir Physiol Neurobiol       Date:  2008-11-18       Impact factor: 1.931

Review 7.  Mast cell peptidases: chameleons of innate immunity and host defense.

Authors:  Neil N Trivedi; George H Caughey
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-20       Impact factor: 6.914

Review 8.  Mast cell plasticity and sphingosine-1-phosphate in immunity, inflammation and cancer.

Authors:  Carole A Oskeritzian
Journal:  Mol Immunol       Date:  2014-04-22       Impact factor: 4.407

9.  IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice.

Authors:  Timothy B Oriss; Mahesh Raundhal; Christina Morse; Rachael E Huff; Sudipta Das; Rachel Hannum; Marc C Gauthier; Kathryn L Scholl; Krishnendu Chakraborty; Seyed M Nouraie; Sally E Wenzel; Prabir Ray; Anuradha Ray
Journal:  JCI Insight       Date:  2017-05-18

10.  VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway.

Authors:  H Aizawa; H Inoue; M Shigyo; S Takata; H Koto; K Matsumoto; N Hara
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.